Navigation Links
Atomic-resolution views suggest function of enzyme that regulates light-detecting signals in eye
Date:10/7/2008

An atomic-resolution view of an enzyme found only in the eye has given researchers at the University of Washington (UW) clues about how this enzyme, essential to vision, is activated. The enzyme, phosphodiesterase 6 (PDE6), is central to the way light entering the retina is converted into a cascade of signals to the brain.

This particular form of the enzyme comes from the cone photoreceptors of the retina and has not been well-researched, in contrast to its rod form. Rods are involved in night vision and motion sensation; the cones are responsible for color sensitivity, visual acuity, daylight vision, and adjustment to bright light.

The section of the enzyme molecule that most interests the researchers is the so-called GAF A domain. A small messenger molecule, cGMP, binds to the GAF A domain to regulate the enzyme.

"The domain binds to this small molecule with extremely high sensitivity," said UW biochemist Clemens Heikaus, who along with Sergio E. Martinez, now a research associate at Rutgers, carried out the study. "From our structure, we can infer why it prefers cGMP over other messenger molecules." He added that the domain is quick in recognizing and responding to the messenger molecule to create an instantaneous flow of information to the brain.

Using X-ray crystallography and nuclear magnetic resonance, the researchers discovered that the enzyme undergoes major structural changes upon binding of the cGMP molecule.

Before binding occurs, the GAF domain is like an outstretched palm with the fingers wiggling, Heikaus said. After the cGMP molecule binds, the GAF domain closes and becomes less dynamic. In this state it looks more like a closed fist.

Further analysis of the consequences of this conformational change may lead to a better understanding of how the photoreceptor PDE helps regulate the path of signals that enable us to see, as well as provide general information on proteins with GAF domains.

"The addition of a simple, small molecule to the GAF domain affects the entire PDE enzyme," Heikaus said. Researchers think the binding to the domain may act as a switch that turns on the enzyme.

The research findings were published in the Sept. 19 Journal of Biological Chemistry. The article was selected as a Paper of the Week. The journal cover featured a striking image of the iris of Heikaus' eye, photographed by UW ophthalmology imaging supervisor Brad Clifton. Superimposed in the center of the pupil was a three-dimensional structure of the GAF domain.

In humans, GAF-containing proteins are rare. In plants and bacteria, GAF domains are widespread and are specialized for binding a variety of molecules. Some of these plant and bacteria GAF domains are important in detecting light, but they do so through a mechanism that is completely different from vision in vertebrate animals.

GAF domains emerged more than 3 billion years ago in early forms of life, and remained as animals and humans evolved, a phenomenon evolutionary biologists call conservation. Human GAF domains have similar protein folds, and a similar way of binding signal-triggering molecules inside a "pocket," as do GAF domains in more primitive creatures.

Humans have only a few kinds of GAF domains, all of which are in enzymes within the PDE family. They perform important functions not only in vision but also in hearts, lungs, and blood vessels. PDE5, an enzyme closely related to PDE6, is the therapeutic target for sildenafil, known by the trade name Viagra. In some men, this drug also inhibits PDE6 in the eyes, causing a temporary change in color vision.

More knowledge of the basic mechanisms of PDEs in vision may lead someday to better drug treatment for loss of eyesight from damaged retinas, such as occurs in night blindness and retinitis pigmentosa.


'/>"/>

Contact: Leila Gray
206-685-0381
University of Washington
Source:Eurekalert  

Related biology news :

1. Priming scientists for successful media interviews
2. Sirtris review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery
3. Features of replication suggest viruses have common themes, vulnerabilities
4. Feeling hot, hot, hot: New study suggests ways to control fever-induced seizures
5. Misconceptions about Alzheimers varies among races, survey suggests
6. Wasp genetics study suggests altruism evolved from maternal behavior
7. Yale discovery suggests protein may play a role in severe asthma
8. Study suggests link between obesity, poor bone health
9. New studies suggest brain overgrowth in 1-year-olds linked to development of autism
10. Threatened birds may be rarer than geographic range maps suggest
11. BMI criteria for obesity surgery should be lowered, UT Southwestern researcher suggests
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Atomic-resolution views suggest function of enzyme that regulates light-detecting signals in eye
(Date:2/16/2017)...  Genos, a community for personal genetic discovery ... Laboratory Accreditation from the College of American Pathologists ... that meet stringent requirements around quality, accuracy and ... "Genos is committed to maintaining the highest ... to be receiving CAP accreditation," said Jill ...
(Date:2/9/2017)... LONDON , Feb. 9, 2017 The ... in-depth analysis of the biomass boiler market globally in ... sales of biomass boilers. The market for biomass boilers ... product type, end-user, application, and country/region. The market based ... agriculture & forest residues, biogas & energy crops, urban ...
(Date:2/8/2017)... -- Report Highlights The global biosurgery market ... in 2016 at a compound annual growth rate (CAGR) ... - An overview of the global market for biosurgery. ... 2015 and 2016, and projections of compound annual growth ... on the basis of product type, source, application, and ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... ... , ... Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery, today ... (NIMH) for the further advancement of the company’s 3-month olanzapine product ( DLP-119 ). ... deliver therapeutic levels of olanzapine for a period of 3 months., “We are honored ...
(Date:2/24/2017)... DIEGO , Feb. 24, 2017  Aethlon Medical, ... following note authored by its Chairman and CEO, ... at the Munich Security Conference last Saturday, Bill ... virus could kill more people than nuclear weapons. Mr. ... U.S. and U.K. intelligence agencies, that scientific terrorists have ...
(Date:2/24/2017)... -- China Cord Blood Corporation (NYSE: CO ... cord blood collection, laboratory testing, hematopoietic stem cell processing ... financial results for the third quarter and first nine ... Third Quarter of Fiscal 2017 Highlights ... 2017 increased by 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... 24, 2017  VWR Corporation (NASDAQ: VWR), the leading global ... production customers, today reported its financial results for the fourth ... Highlights: 4Q16 record quarterly net sales ... an organic basis. 4Q16 EMEA-APAC ... basis, while the Americas net sales increased 2.5%, or down ...
Breaking Biology Technology: